Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: A population-based study and first report

Cancer

Volumn 116, Issue 11, 2010, Pages 2549-2559

  Lund, Mary Jo ^a,b,c   Butler, Ebonee N ^a   Hair, Brionna Y ^a   Ward, Kevin C ^a,d   Andrews, Judy H ^a,d   Oprea Ilies, Gabriella ^c   Bayakly, A Rana ^e   O'Regan, Ruth M ^c   Vertino, Paula M ^c   Eley, J William ^c  

^a EMORY UNIVERSITY   (United States)

^b Georgia Cancer Center for Excellence at Grady   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Georgia Center for Cancer Statistics   (United States)

^e Georgia Comprehensive Cancer Registry   (United States)

Author keywords

Breast cancer; Disparity; HER2 testing; Incidence; Race; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; BREAST CANCER; CANCER INCIDENCE; CAUCASIAN; EARLY CANCER; ETHNIC DIFFERENCE; FEMALE; GROUPS BY AGE; HISPANIC; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; POPULATION RESEARCH; PRIMARY TUMOR; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIAL STATUS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HUMANS; MIDDLE AGED; POPULATION SURVEILLANCE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77952826682     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25016     Document Type: Article

References (47)

1. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, Ga: American Cancer Society; 2009.
2. Amend K, Hicks D, Ambrosone C. Breast cancer in African- American women: differences in tumor biology from European-American women. Cancer Res. 2006;66:8327-8330. (Pubitemid 44449138)
3. Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol. 2006;33:621-632. (Pubitemid 44669717)
4. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97:439-448. (Pubitemid 40528607)
5. Cleator S, Ashworth A. Molecular profiling of breast cancer: clinical implications. Br J Cancer. 2004;90:1120-1124. (Pubitemid 38496800)
6. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40: 2667-2675. (Pubitemid 39574720)
7. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262-272.
8. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536. Comment in: Nature. 2002;415: 484-485
9. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
10. Bast RC, Jr., Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
11. Havener L, Hulstrom D. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Eleventh Edition, Version 11.1. Springfield, Ill: North American Association of Central Cancer Registries; 2006.
12. Johnson CH, Adamo M. SEER Program Coding and Staging Manual. Bethesda, Md: National Cancer Institute; 2007. NIH publication no. 07-5581.
13. National Comprehensive Cancer Center Clinical Practice Guidelines in Oncology, Breast Cancer Version 2. 2006. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/breast.pdf.
14. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001;19:3817-3827.
15. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003; 21:3357-3365. (Pubitemid 46606270)
16. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684. (Pubitemid 41464706)
17. Slamon DJ, Romond EH, Perez EA, et al. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol. 2006;4(3 suppl 7) suppl 1, 4-9.
18. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat. 2005;90:127-137. (Pubitemid 40568896)
19. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol. 2001;19:972-979. (Pubitemid 32176271)
20. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116: 340-350. (Pubitemid 40993329)
21. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer. 2007; 109:1721-1728 (Pubitemid 46668532)
22. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502. (Pubitemid 43854964)
23. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235-244. (Pubitemid 46291713)
24. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98:10869-10874. (Pubitemid 32878711)
25. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652-5657. (Pubitemid 46631305)
26. Lund MJ, Trivers KL, Porter PL, et al: Race and triple negative threats to breast cancer survival. Breast Cancer Res Treat. 2009;113:357-370.
27. Gwyn K, Bondy ML, Cohen DS, et al. Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer. 2004;100:1595-1600.
28. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49-56. (Pubitemid 36091600)
29. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006;24:1357-1362. (Pubitemid 46621998)
30. Lund MJ, Brawley OW, Ward KC, et al. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2008;109:545-557. (Pubitemid 351692062)
31. Porter PL, Lund MJ, Lin MG, et al. Racial differences in expression of cell cycle regulatory proteins in breast cancer: Study of young African American and white women in Atlanta. Cancer. 2004;100:2533-2542.
32. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003;97:134-147.
33. Chu KC, Anderson WF, Fritz A, et al. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ ethnic groups. Cancer. 2001;92:37-45. (Pubitemid 32623038)
34. SecureAction. Advanced Encryption Package 2007. Available at: http://www.secureaction.com. Accessed on February 4, 2007.
35. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
36. US Bureau of the Census. Census of population and housing: 2000 [summary file 3, technical documentation]. Washington, DC: US Bureau of the Census; 2002.
37. Krieger N, Chen JT, Waterman PD, et al. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures - the public health disparities geocoding project. Am J Public Health. 2003;93:1655-1671. (Pubitemid 38477631)
38. US Bureau of the Census. Poverty areas. Available at: http://www.census.gov/hhes/www/poverty/definitions.html. Accessed on August 5, 2007.
39. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182. (Pubitemid 36245750)
40. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
41. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127. (Pubitemid 44027496)
42. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27-41.
43. National Health Interview Survey. National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention, 2004. Available at: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/04349.
44. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 pt 1):4429-4434. (Pubitemid 47219710)
45. Center for Disease Control. National Program for Cancer Registries; 2009 NPCR-CSS Submission Specifications. Available at: http://www.cdc.gov/cancer/ npcr/.
46. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-10398. (Pubitemid 37071889)
47. Schneider BP, Winer EP, Foulkes WD et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010-8017.